A phase III trial of CA-002 for the treatment of peanut allergies: A randomized, double-blind, placebo-controlled study
Latest Information Update: 19 Jan 2024
At a glance
- Drugs CA 002 (Primary)
- Indications Peanut hypersensitivity
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Camallergy
- 08 Jan 2021 According to a Camallergy media release, company is planning IND (Investigational New Drug) and IMPD (Investigational Medicinal Product Dossier) applications in the US, UK, and EU to initiate our pivotal Phase 3 studies to commence this year upon the closing of our Series B round
- 06 Nov 2019 According to a Camallergy media release, the company plans to initiate a randomized, double-blind, placebo-controlled Phase 3 clinical trial by mid-year 2020.
- 26 Oct 2018 New trial record